Sinoway Industrial Co., Ltd.

Imatinib Mesylate 220127-57-1 Imatinib Mesylate 220127-57-1

Imatinib Mesylate 220127-57-1
Related Products
  • L-Glutathione Reduced (GSH) 70-18-8

    L-Glutathione ReducedBasic information of L-Glutathione Reduced:Product name: L-Glutathione ReducedMolecular Formula : C20H32N6O12S2Molecular Weight: 612.63CAS No.:70-18-8ENIECE No: 200-725-4Appearanc...

  • Copper Peptide (GHK)2-CU 49557-75-7

    Copper peptide GHK-CuBasic information of copper peptide GHK-Cu :Product Name(GHK)2-Cu(Copper Peptide)SynonymsGHK-Cu (Copper peptide)CAS #49557-75-7Molecular FormulaC28H46N12O8Cu Molecular Weight742.2...

  • Isoflavones in Soy 574-12-9

    Soybean Extract1.Basic information of Soybean Extract:Product name: Soybean ExtractSource: glycine maxUsed part: germ/bean pulpSpec.: total soy isoflavone 40%, 80% by HPLCNameSoybean Extract PowderTyp...

Basic information of Imatinib Mesylate

Name

Imatinib Mesylate

Alias

GLIVEC;GLEEVEC;IMATINIB METHANESULFONATE; CGP-57148B;
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]-phenyl]-benzamide Mesylate;

CAS NO.

220127-57-1

Molecular Formula

C30H35N7O4S

Molecular Weight

589.71

Quality Standard

In-house Standard

Package Size

Aluminium bag; 50g/bag; 100g/bag

Brief Introduction

Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl,
the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of
dermatological diseases. Imatinib has been reported to be an effective treatment for
FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.

Storage condition

Preserve in tight, light-resistant containers, and store at 15℃—30℃.

Use of Imatinib Mesylate

  • A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)
  • echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis
  • Anticancer

COA of Imatinib Mesylate

TEST ITEM

SPECIFICATION

RESULTS

Appearance

White or slightly yellow crystalline powder,
homogeneous and with fine grain size.
No foreign particles are observed.

Slightly yellow crystalline Powder

Solubility

Soluble in water and in acids solutions, slightly soluble
in methanol insoluble in acetone, acetonitrile and
dilute hydroxyl alkaline solution

Confirm

Identification

Complies

Confirm

Water

≤1.0%

0.8%

Heavy metals

≤20ppm

10ppm

Melting range

212 – 220℃

214-216℃

Residue on ignition

≤0.1%

0.08%

Particle size

90% < 100 μm

50% < 50 μm

Confirm

Bulk density

NLT 0.4g/ml

0.6g/ml

Chromatographic

purity

Individual impurities: ≤0.2%

Total impurities: ≤0.5%

0.16%

0.32%

Assay

98.5%-102.0% of Imatinib mesylate,

calculated on anhydrous basis.

99.70%



Residual solvents

Ethyl acetate: ≤5000ppm

Confirm

Acetone: ≤5000ppm

Confirm

N,N-Dimethylformamide: ≤880ppm

Confirm

Methanol: ≤3000ppm

Confirm

Dichloromethane: ≤300ppm

Confirm



MORE_DETAIL Imatinib Mesylate 220127-57-1

Basic information of Imatinib Mesylate

Name

Imatinib Mesylate

Alias

GLIVEC;GLEEVEC;IMATINIB METHANESULFONATE; CGP-57148B;
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]-phenyl]-benzamide Mesylate;

CAS NO.

220127-57-1

Molecular Formula

C30H35N7O4S

Molecular Weight

589.71

Quality Standard

In-house Standard

Package Size

Aluminium bag; 50g/bag; 100g/bag

Brief Introduction

Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl,
the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of
dermatological diseases. Imatinib has been reported to be an effective treatment for
FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.

Storage condition

Preserve in tight, light-resistant containers, and store at 15℃—30℃.

Use of Imatinib Mesylate

  • A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)
  • echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis
  • Anticancer

COA of Imatinib Mesylate

TEST ITEM

SPECIFICATION

RESULTS

Appearance

White or slightly yellow crystalline powder,
homogeneous and with fine grain size.
No foreign particles are observed.

Slightly yellow crystalline Powder

Solubility

Soluble in water and in acids solutions, slightly soluble
in methanol insoluble in acetone, acetonitrile and
dilute hydroxyl alkaline solution

Confirm

Identification

Complies

Confirm

Water

≤1.0%

0.8%

Heavy metals

≤20ppm

10ppm

Melting range

212 – 220℃

214-216℃

Residue on ignition

≤0.1%

0.08%

Particle size

90% < 100 μm

50% < 50 μm

Confirm

Bulk density

NLT 0.4g/ml

0.6g/ml

Chromatographic

purity

Individual impurities: ≤0.2%

Total impurities: ≤0.5%

0.16%

0.32%

Assay

98.5%-102.0% of Imatinib mesylate,

calculated on anhydrous basis.

99.70%



Residual solvents

Ethyl acetate: ≤5000ppm

Confirm

Acetone: ≤5000ppm

Confirm

N,N-Dimethylformamide: ≤880ppm

Confirm

Methanol: ≤3000ppm

Confirm

Dichloromethane: ≤300ppm

Confirm


Related Articles
Leave a Message Email Us

we will contact you within 24 hours.

  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//